BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  GeoVax’s Novel Vaccine Platform Induces Both Antibody and T Cell Responses

  GeoVax is conducting two Phase II COVID-19 vaccine clinical trials with its GEO-CMO4S1 vaccine. One of the trials is among immunocompromised patients.

  April 8, 2022

   · 

  5 min read

   · 

  Gail Dutton
• 

  Policy

  Janssen Victorious in Arbitration Battle Vs. Genmab over Darzalex Royalties

  Janssen Pharmaceutical, under parent organization Johnson & Johnson, secured an arbitrary win this week that results in royalty decisions stemming from licensing and marketing of daratumumab.

  April 8, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano, M.S.
• 

  Scientists Turn Back the Clock, Make Skin Cells 30 Years Younger

  Researchers at the Babraham Research Institute have developed a new technique for rejuvenating skin cells, which can rewind the biological clock of patients by about 30 years.

  April 8, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Business

  Everybody Wants a Piece of Moderna. Next Up: University of Toronto

  The partnership framework agreement allows Moderna and U of T to collaborate across a broad variety of areas, ranging from molecular genetics to biomedical engineering, biochemistry and more.

  April 8, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  FDA

  Alnylam’s Greenstreet Takes Home $8.5M, Ex-CEO Maraganore Nets $10M

  Alnylam Pharmaceuticals issued a proxy filing ahead of its May 18, 2022, Annual Meeting of Stockholders to inform stockholders of several items they can vote on at the end of the meeting.

  April 8, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Deals

  Kaleido Biosciences Culls Staff, Prepares to Cease Operations

  Shares of Kaleido Biosciences are plunging after the company announced its intentions to cease all company operations, lay off its remaining staff and delist from the Nasdaq Exchange.

  April 8, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Study: Psilocybin (Magic Mushrooms) May Curb Opioid Use Disorder

  Classical psychedelics are showing promising results in treating opioid use disorder. How they aim to do that can be found here in the article.

  April 8, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  GENFIT Recovers Post-Pandemic with Key Studies On ACLF and Cholestatic Diseases

  GENFIT delivered on its promise to improve its financial situation in the year to December 31, 2021, posting an income of $40.8 million USD from a loss of $20.3 million in the year prior.

  April 8, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Policy

  US Congress Introduces Bills to Strengthen Pharma Competition, Promote Innovation

  The new bills result from a three-year investigation that honed in on anti-competitive efforts that have prevented generic drugs and biosimilars from entering the market.

  April 8, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  FDA

  In Leap Forward, Triastek Takes 3D-Printed Cardiovascular Drug into the Clinic

  The U.S. FDA greenlit China-based Triastek’s IND Application for its 3D printed drug product, T20, for cardiovascular and clotting disorders.

  April 8, 2022

   · 

  2 min read

   · 

  Alex Keown